Anika Therapeutics (ANIK) Accumulated Expenses (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Accumulated Expenses data on file, last reported at $6.8 million in Q1 2026.

• On a quarterly basis, Accumulated Expenses fell 46.11% year-over-year to $6.8 million in Q1 2026; TTM through Mar 2026 was $6.8 million, a 46.11% decrease from a year earlier, with the FY2025 full-year figure at $15.9 million, up 132.38% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $6.8 million, down from $15.9 million in the prior quarter.
• Over the last five years, Accumulated Expenses for ANIK reached as high as $19.7 million in Q1 2023 and fell as low as $6.8 million in Q1 2026.
• Historically, Accumulated Expenses has averaged $13.5 million across 5 years, with a median of $14.1 million in 2023.
• Across the five-year window, Accumulated Expenses soared 164.78% in 2023 and tumbled 56.6% in 2025, its largest moves.
• Year by year, Accumulated Expenses stood at $11.3 million in 2022, then rose by 24.44% to $14.1 million in 2023, then plunged by 51.46% to $6.8 million in 2024, then jumped by 132.38% to $15.9 million in 2025, then sank by 57.12% to $6.8 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $6.8 million in Q1 2026, $15.9 million in Q4 2025, and $8.1 million in Q3 2025.